Advertisement

The acceleration of ageing in older patients with cancer

Published:September 12, 2020DOI:https://doi.org/10.1016/j.jgo.2020.09.010

      Abstract

      Older cancer survivors may experience ageing at an accelerated rate when compared to their similar-aged, cancer-free counterparts. Ageing is undoubtedly a significant risk factor for cancer. There is evidence to suggest, however, that this relationship may in fact be bidirectional, with cancer and its treatments contributing to the ageing process. In this review, we outline the current literature linking cancer and anti-cancer therapy to adverse ageing outcomes and explore what additional research is needed in order to conclusively define cancer and its treatment as an accelerator of ageing.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.L.
        • Torre L.A.
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424https://doi.org/10.3322/caac.21492
      1. Australian Cancer Incidence and Mortality (ACIM) books. Australian Institute of Health and Welfare, Canberra2018
        • Howlander N.
        • Noone A.
        • Krapcho M.
        • Miller D.
        • Brest A.
        • Yu M.
        • et al.
        SEER Cancer statistics review, 1975–2016.
        National Cancer Institute, Bethesda, MD2018
        • Denlinger C.S.
        • Carlson R.W.
        • Are M.
        • Baker K.S.
        • Davis E.
        • Edge S.B.
        • et al.
        Survivorship: introduction and definition. Clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2014; 12: 34-45https://doi.org/10.6004/jnccn.2014.0005
        • Bluethmann S.M.
        • Mariotto A.B.
        • Rowland J.H.
        Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older Cancer survivors in the United States.
        Cancer Epidemiol Biomarkers Prev. 2016; 25: 1029-1036https://doi.org/10.1158/1055-9965.EPI-16-0133
        • Armenian S.H.
        • Gibson C.J.
        • Rockne R.C.
        • Ness K.K.
        Premature aging in young cancer survivors.
        J Natl Cancer Inst. 2019; 111: 226-232https://doi.org/10.1093/jnci/djy229
        • Guida J.L.
        • Ahles T.A.
        • Belsky D.
        • Campisi J.
        • Cohen H.J.
        • DeGregori J.
        • et al.
        Measuring aging and identifying aging phenotypes in cancer survivors.
        J Natl Cancer Inst. 2019; 111: 1245-1254https://doi.org/10.1093/jnci/djz136
        • Henderson TO
        • Ness K.K.
        • Cohen H.J.
        Accelerated aging among cancer survivors: from pediatrics to geriatrics.
        Am Soc Clin Oncol Educ Book. 2014; (e423–30)https://doi.org/10.14694/EdBook_AM.2014.34.e423
        • Hurria A.
        • Jones L.
        • Muss H.B.
        Cancer treatment as an accelerated aging process: assessment, biomarkers, and interventions.
        Am Soc Clin Oncol Educ Book. 2016; 35 (e516–22)https://doi.org/10.14694/EDBK_15616010.1200/EDBK_156160
        • What is cancer?
        National Cancer Institute.
        ([Available from)
        • I. BA, C. C
        Chapter 2, Carcinogenesis.
        The Publishing House of the Romanian Academy, 2007
        • Klaunig J.E.
        • Xu Y.
        • Isenberg J.S.
        • Bachowski S.
        • Kolaja K.L.
        • Jiang J.
        • et al.
        The role of oxidative stress in chemical carcinogenesis.
        Environ Health Perspect. 1998; 106: 289-295https://doi.org/10.1289/ehp.98106s1289
        • Maynard S.
        • Fang E.F.
        • Scheibye-Knudsen M.
        • Croteau D.L.
        • Bohr V.A.
        DNA damage, DNA repair, aging, and neurodegeneration.
        Cold Spring Harb Perspect Med. 2015; 5https://doi.org/10.1101/cshperspect.a025130
        • DiLoreto R.
        • Murphy C.T.
        The cell biology of aging.
        Mol Biol Cell. 2015; 26: 4524-4531https://doi.org/10.1091/mbc.E14-06-1084
        • Smetana Jr., K.
        • Lacina L.
        • Szabo P.
        • Dvorankova B.
        • Broz P.
        • Sedo A.
        Ageing as an important risk factor for cancer.
        Anticancer Res. 2016; 36: 5009-5017https://doi.org/10.21873/anticanres.11069
        • Maccormick R.E.
        Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty?.
        Med Hypotheses. 2006; 67: 212-215https://doi.org/10.1016/j.mehy.2006.01.045
        • Ahles T.A.
        • Saykin A.J.
        • McDonald B.C.
        • Furstenberg C.T.
        • Cole B.F.
        • Hanscom B.S.
        • et al.
        Cognitive function in breast cancer patients prior to adjuvant treatment.
        Breast Cancer Res Treat. 2008; 110: 143-152https://doi.org/10.1007/s10549-007-9686-5
        • Bylow K.
        • Hemmerich J.
        • Mohile S.G.
        • Stadler W.M.
        • Sajid S.
        • Dale W.
        Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.
        Urology. 2011; 77: 934-940https://doi.org/10.1016/j.urology.2010.11.024
        • Correa D.D.
        • DeAngelis L.M.
        • Shi W.
        • Thaler H.
        • Glass A.
        • Abrey L.E.
        Cognitive functions in survivors of primary central nervous system lymphoma.
        Neurology. 2004; 62: 548-555https://doi.org/10.1212/01.wnl.0000109673.75316.d8
        • LM DeAngelis
        Neurologic Complications of Cancer. Holland-Frei Cancer Medicine.
        2017: 1-15
        • Decoster L.
        • Kenis C.
        • Schallier D.
        • Vansteenkiste J.
        • Nackaerts K.
        • Vanacker L.
        • et al.
        Geriatric assessment and functional decline in older patients with lung cancer.
        Lung. 2017; 195: 619-626https://doi.org/10.1007/s00408-017-0025-2
        • Dietrich J.
        • Han R.
        • Yang Y.
        • Mayer-Proschel M.
        • Noble M.
        CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.
        J Biol. 2006; 5: 22https://doi.org/10.1186/jbiol50
        • Dietrich J.
        • Monje M.
        • Wefel J.
        • Meyers C.
        Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy.
        Oncologist. 2008; 13: 1285-1295https://doi.org/10.1634/theoncologist.2008-0130
        • Greene-Schloesser D.
        • Robbins M.E.
        • Peiffer A.M.
        • Shaw E.G.
        • Wheeler K.T.
        • Chan M.D.
        Radiation-induced brain injury: a review.
        Front Oncol. 2012; 2: 73https://doi.org/10.3389/fonc.2012.00073
        • Hodgson K.D.
        • Hutchinson A.D.
        • Wilson C.J.
        • Nettelbeck T.
        A meta-analysis of the effects of chemotherapy on cognition in patients with cancer.
        Cancer Treat Rev. 2013; 39: 297-304https://doi.org/10.1016/j.ctrv.2012.11.001
        • Jim H.S.
        • Phillips K.M.
        • Chait S.
        • Faul L.A.
        • Popa M.A.
        • Lee Y.H.
        • et al.
        Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.
        J Clin Oncol. 2012; 30: 3578-3587https://doi.org/10.1200/JCO.2011.39.5640
        • Pai V.B.
        • Nahata M.C.
        Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
        Drug Saf. 2000; 22: 263-302https://doi.org/10.2165/00002018-200022040-00002
        • Sahni V.
        • Choudhury D.
        • Ahmed Z.
        Chemotherapy-associated renal dysfunction.
        Nat Rev Nephrol. 2009; 5: 450-462https://doi.org/10.1038/nrneph.2009.97
        • Scott J.N.
        • Rewcastle N.B.
        • Brasher P.M.
        • Fulton D.
        • MacKinnon J.A.
        • Hamilton M.
        • et al.
        Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.
        Ann Neurol. 1999; 46: 183-188https://doi.org/10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7
        • Shilling V.
        • Jenkins V.
        • Morris R.
        • Deutsch G.
        • Bloomfield D.
        The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.
        Breast. 2005; 14: 142-150https://doi.org/10.1016/j.breast.2004.10.004
        • Ward P.R.
        • Wong M.D.
        • Moore R.
        • Naeim A.
        Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study.
        J Geriatr Oncol. 2014; 5: 57-64https://doi.org/10.1016/j.jgo.2013.10.002
        • Wefel J.S.
        • Lenzi R.
        • Theriault R.L.
        • Davis R.N.
        • Meyers C.A.
        The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.
        Cancer. 2004; 100: 2292-2299https://doi.org/10.1002/cncr.20272
        • Winocur G.
        • Vardy J.
        • Binns M.A.
        • Kerr L.
        • Tannock I.
        The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice.
        Pharmacol Biochem Behav. 2006; 85: 66-75https://doi.org/10.1016/j.pbb.2006.07.010
        • Winters-Stone K.M.
        • Moe E.
        • Graff J.N.
        • Dieckmann N.F.
        • Stoyles S.
        • Borsch C.
        • et al.
        Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy.
        J Am Geriatr Soc. 2017; 65: 1414-1419https://doi.org/10.1111/jgs.14795
        • Winters-Stone K.M.
        • Torgrimson B.
        • Horak F.
        • Eisner A.
        • Nail L.
        • Leo M.C.
        • et al.
        Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach.
        Arch Phys Med Rehabil. 2011; 92: 646-652https://doi.org/10.1016/j.apmr.2010.10.039
        • Wu F.J.
        • Sheu S.Y.
        • Lin H.C.
        • Chung S.D.
        Increased fall risk in patients receiving androgen deprivation therapy for prostate cancer.
        Urology. 2016; 95: 145-150https://doi.org/10.1016/j.urology.2016.05.058
        • Sanoff H.K.
        • Deal A.M.
        • Krishnamurthy J.
        • Torrice C.
        • Dillon P.
        • Sorrentino J.
        • et al.
        Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.
        J Natl Cancer Inst. 2014; 106 (dju057)https://doi.org/10.1093/jnci/dju057
        • Calder P.C.
        • Ahluwalia N.
        • Albers R.
        • Bosco N.
        • Bourdet-Sicard R.
        • Haller D.
        • et al.
        A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies.
        Br J Nutr. 2013; 109: S1-34https://doi.org/10.1017/S0007114512005119
        • Ferrucci L.
        • Fabbri E.
        Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.
        Nat Rev Cardiol. 2018; 15: 505-522https://doi.org/10.1038/s41569-018-0064-2
        • Straub R.H.
        • Cutolo M.
        • Pacifici R.
        Evolutionary medicine and bone loss in chronic inflammatory diseases--a theory of inflammation-related osteopenia.
        Semin Arthritis Rheum. 2015; 45: 220-228https://doi.org/10.1016/j.semarthrit.2015.04.014
        • Taphoorn M.J.
        • Schiphorst A.K.
        • Snoek F.J.
        • Lindeboom J.
        • Wolbers J.G.
        • Karim A.B.
        • et al.
        Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.
        Ann Neurol. 1994; 36: 48-54https://doi.org/10.1002/ana.410360111
        • Vardy J.L.
        • Dhillon H.M.
        • Pond G.R.
        • Rourke S.B.
        • Bekele T.
        • Renton C.
        • et al.
        Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal.
        Control Stud J Clin Oncol. 2015; 33: 4085-4092https://doi.org/10.1200/JCO.2015.63.0905
        • Ahles T.A.
        • Hurria A.
        New challenges in psycho-oncology research IV: cognition and cancer: conceptual and methodological issues and future directions.
        Psychooncology. 2018; 27: 3-9https://doi.org/10.1002/pon.4564
        • Margolick J.B.
        • Ferrucci L.
        Accelerating aging research: how can we measure the rate of biologic aging?.
        Exp Gerontol. 2015; 64: 78-80https://doi.org/10.1016/j.exger.2015.02.009
        • Harada C.N.
        • Natelson Love M.C.
        • Triebel K.L.
        Normal cognitive aging.
        Clin Geriatr Med. 2013; 29: 737-752https://doi.org/10.1016/j.cger.2013.07.002
        • Kim J.H.
        • Brown S.L.
        • Jenrow K.A.
        • Ryu S.
        Mechanisms of radiation-induced brain toxicity and implications for future clinical trials.
        J Neurooncol. 2008; 87: 279-286https://doi.org/10.1007/s11060-008-9520-x
        • Schiff D.
        • Wen P.Y.
        Cancer Neurology in Clinical Practice.
        Humana Press, 2002
        • Talacchi A.
        • Santini B.
        • Savazzi S.
        • Gerosa M.
        Cognitive effects of tumour and surgical treatment in glioma patients.
        J Neurooncol. 2011; 103: 541-549https://doi.org/10.1007/s11060-010-0417-0
        • Meyers C.A.
        • Smith J.A.
        • Bezjak A.
        • Mehta M.P.
        • Liebmann J.
        • Illidge T.
        • et al.
        Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
        J Clin Oncol. 2004; 22: 157-165https://doi.org/10.1200/JCO.2004.05.128
        • La Carpia D.
        • Liperoti R.
        • Guglielmo M.
        • Di Capua B.
        • Devizzi L.F.
        • Matteucci P.
        • et al.
        Cognitive decline in older long-term survivors from Non-Hodgkin lymphoma: a multicenter cross-sectional study.
        J Geriatr Oncol. 2020; https://doi.org/10.1016/j.jgo.2020.01.007
        • van der Willik K.D.
        • Hauptmann M.
        • Jozwiak K.
        • Vinke E.J.
        • Ruiter R.
        • Stricker B.H.
        • et al.
        Trajectories of cognitive function prior to cancer diagnosis: a population-based study.
        J Natl Cancer Inst. 2020; 112: 480-488https://doi.org/10.1093/jnci/djz178
        • Padgett L.S.
        • Van Dyk K.
        • Kelly N.C.
        • Newman R.
        • Hite S.
        • Asher A.
        Addressing cancer-related cognitive impairment in cancer survivorship.
        Oncol Issues. 2020; 35: 52-57https://doi.org/10.1080/10463356.2020.1692601
        • Falleti M.G.
        • Sanfilippo A.
        • Maruff P.
        • Weih L.
        • Phillips K.A.
        The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.
        Brain Cogn. 2005; 59: 60-70https://doi.org/10.1016/j.bandc.2005.05.001
        • Stewart A.
        • Bielajew C.
        • Collins B.
        • Parkinson M.
        • Tomiak E.
        A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.
        Clin Neuropsychol. 2006; 20: 76-89https://doi.org/10.1080/138540491005875
        • Zimmer P.
        • Mierau A.
        • Bloch W.
        • Struder H.K.
        • Hulsdunker T.
        • Schenk A.
        • et al.
        Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.
        Leuk Lymphoma. 2015; 56: 347-352https://doi.org/10.3109/10428194.2014.915546
        • Meade T.
        • Cumming S.
        • Hallab L.
        • Spencer D.
        • Howe G.
        • Manolios N.
        A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment.
        J Health Psychol. 2013; 18: 1353-1359https://doi.org/10.1177/1359105312461660
        • Varney N.R.
        • Alexander B.
        • MacIndoe J.H.
        Reversible steroid dementia in patients without steroid psychosis.
        Am J Psychiatry. 1984; 141: 369-372https://doi.org/10.1176/ajp.141.3.369
        • Judge A.
        • Garriga C.
        • Arden N.K.
        • Lovestone S.
        • Prieto-Alhambra D.
        • Cooper C.
        • et al.
        Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients.
        Alzheimers Dement (N Y). 2017; 3: 612-621https://doi.org/10.1016/j.trci.2017.10.002
        • Olah C.
        • Kardos Z.
        • Andrejkovics M.
        • Szarka E.
        • Hodosi K.
        • Domjan A.
        • et al.
        Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety.
        Rheumatol Int. 2020; 40: 529-540https://doi.org/10.1007/s00296-019-04449-8
        • Meade T.
        • Manolios N.
        • Cumming S.R.
        • Conaghan P.G.
        • Katz P.
        Cognitive impairment in rheumatoid arthritis: a systematic review.
        Arthritis Care Res (Hoboken). 2018; 70: 39-52https://doi.org/10.1002/acr.23243
        • Buchner D.M.
        • Wagner E.H.
        Preventing frail health.
        Clin Geriatr Med. 1992; 8: 1-17https://doi.org/10.1016/S0749-0690(18)30494-4
        • De Alfieri W.
        • Costanzo S.
        • Borgogni T.
        Biological resilience of older adults versus frailty.
        Med Hypotheses. 2011; 76: 304-305https://doi.org/10.1016/j.mehy.2010.11.028
        • Fried L.P.
        • Tangen C.M.
        • Walston J.
        • Newman A.B.
        • Hirsch C.
        • Gottdiener J.
        • et al.
        Frailty in older adults: evidence for a phenotype.
        J Gerontol A Biol Sci Med Sci. 2001; 56: M146-M156https://doi.org/10.1093/gerona/56.3.m146
        • Sayer A.A.
        • Kirkwood T.B.
        Grip strength and mortality: a biomarker of ageing?.
        Lancet. 2015; 386: 226-227https://doi.org/10.1016/S0140-6736(14)62349-7
        • Mohile S.G.
        • Dale W.
        • Somerfield M.R.
        • Schonberg M.A.
        • Boyd C.M.
        • Burhenn P.S.
        • et al.
        Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology.
        J Clin Oncol. 2018; 36: 2326-2347https://doi.org/10.1200/JCO.2018.78.8687
        • de Vries N.M.
        • Staal J.B.
        • van Ravensberg C.D.
        • Hobbelen J.S.
        • Olde Rikkert M.G.
        • Nijhuis-van der Sanden M.W.
        Outcome instruments to measure frailty: a systematic review.
        Ageing Res Rev. 2011; 10: 104-114https://doi.org/10.1016/j.arr.2010.09.001
        • Bennett J.A.
        • Winters-Stone K.M.
        • Dobek J.
        • Nail L.M.
        Frailty in older breast cancer survivors: age, prevalence, and associated factors.
        Oncol Nurs Forum. 2013; 40: E126-E134https://doi.org/10.1188/13.ONF.E126-E134
        • Leidy N.K.
        Functional status and the forward progress of merry-go-rounds: toward a coherent analytical framework.
        Nurs Res. 1994; 43: 196-202https://doi.org/10.1097/00006199-199407000-00002
        • Petrick J.L.
        • Reeve B.B.
        • Kucharska-Newton A.M.
        • Foraker R.E.
        • Platz E.A.
        • Stearns S.C.
        • et al.
        Functional status declines among cancer survivors: trajectory and contributing factors.
        J Geriatr Oncol. 2014; 5: 359-367https://doi.org/10.1016/j.jgo.2014.06.002
        • Wensing M.
        • Vingerhoets E.
        • Grol R.
        Functional status, health problems, age and comorbidity in primary care patients.
        Qual Life Res. 2001; 10: 141-148https://doi.org/10.1023/a:1016705615207
        • van Abbema D.
        • van Vuuren A.
        • van den Berkmortel F.
        • van den Akker M.
        • Deckx L.
        • Buntinx F.
        • et al.
        Functional status decline in older patients with breast and colorectal cancer after cancer treatment: a prospective cohort study.
        J Geriatr Oncol. 2017; 8: 176-184https://doi.org/10.1016/j.jgo.2017.01.003
        • Granger C.L.
        • McDonald C.F.
        • Irving L.
        • Clark R.A.
        • Gough K.
        • Murnane A.
        • et al.
        Low physical activity levels and functional decline in individuals with lung cancer.
        Lung Cancer. 2014; 83: 292-299https://doi.org/10.1016/j.lungcan.2013.11.014
        • Suastika K.
        • Dwipayana P.
        • Semadi M.S.
        • Kuswardhani R.T.
        Age is an important risk factor for type 2 diabetes mellitus and cardiovascular diseases.
        in: Chackrewarthy S. Glucose. IntechOpen, Tolerance2012
        • North B.J.
        • Sinclair D.A.
        The intersection between aging and cardiovascular disease.
        Circ Res. 2012; 110: 1097-1108https://doi.org/10.1161/CIRCRESAHA.111.246876
        • Ng H.S.
        • Roder D.
        • Koczwara B.
        • Vitry A.
        Comorbidity, physical and mental health among cancer patients and survivors: an Australian population-based study.
        Asia Pac J Clin Oncol. 2018; 14 (e181-e92)https://doi.org/10.1111/ajco.12677
        • Hovaldt H.B.
        • Suppli N.P.
        • Olsen M.H.
        • Steding-Jessen M.
        • Hansen D.G.
        • Moller H.
        • et al.
        Who are the cancer survivors? A nationwide study in Denmark, 1943-2010.
        Br J Cancer. 2015; 112: 1549-1553https://doi.org/10.1038/bjc.2015.68
        • Strongman H.
        • Gadd S.
        • Matthews A.
        • Mansfield K.E.
        • Stanway S.
        • Lyon A.R.
        • et al.
        Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
        Lancet. 2019; 394: 1041-1054https://doi.org/10.1016/S0140-6736(19)31674-5
        • Ness K.K.
        • Oakes J.M.
        • Punyko J.A.
        • Baker K.S.
        • Gurney J.G.
        Prevalence of the metabolic syndrome in relation to self-reported cancer history.
        Ann Epidemiol. 2005; 15: 202-206https://doi.org/10.1016/j.annepidem.2004.07.092
        • Braga-Basaria M.
        • Dobs A.S.
        • Muller D.C.
        • Carducci M.A.
        • John M.
        • Egan J.
        • et al.
        Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
        J Clin Oncol. 2006; 24: 3979-3983https://doi.org/10.1200/JCO.2006.05.9741
        • Niccoli T.
        • Partridge L.
        Ageing as a risk factor for disease.
        Curr Biol. 2012; 22: R741-R752https://doi.org/10.1016/j.cub.2012.07.024
        • Epping-Jordan J.E.
        • Galea G.
        • Tukuitonga C.
        • Beaglehole R.
        Preventing chronic diseases: taking stepwise action.
        Lancet. 2005; 366: 1667-1671https://doi.org/10.1016/S0140-6736(05)67342-4
        • de Haas E.C.
        • Oosting S.F.
        • Lefrandt J.D.
        • Wolffenbuttel B.H.
        • Sleijfer D.T.
        • Gietema J.A.
        The metabolic syndrome in cancer survivors.
        Lancet Oncol. 2010; 11: 193-203https://doi.org/10.1016/S1470-2045(09)70287-6
        • Mantovani A.
        • Allavena P.
        • Sica A.
        • Balkwill F.
        Cancer-related inflammation.
        Nature. 2008; 454: 436-444https://doi.org/10.1038/nature07205
        • Straub R.H.
        The brain and immune system prompt energy shortage in chronic inflammation and ageing.
        Nat Rev Rheumatol. 2017; 13: 743-751https://doi.org/10.1038/nrrheum.2017.172
        • Chabner B.A.
        Antineoplastic Agents.
        McGraw-Hill, 1996: 1389-1459
        • Gewirtz D.
        A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
        Biochem Pharmacol. 1999; 57: 727-741https://doi.org/10.1016/S0006-2952(98)00307-4
        • Burger R.M.
        • Projan S.J.
        • Horwitz S.B.
        • Peisach J.
        The DNA cleavage mechanism of iron-bleomycin. Kinetic resolution of strand scission from base propenal release.
        J Biol Chem. 1986; 261: 15955-15959
        • Valavaara R.
        • Nordman E.
        Renal complications of mitomycin C therapy with special reference to the total dose.
        Cancer. 1985; 55: 47-50https://doi.org/10.1002/1097-0142(19850101)55:1<47::aid-cncr2820550108>3.0.co;2-#
        • Beretta G.L.
        • Zunino F.
        Molecular mechanisms of anthracycline activity.
        Top Curr Chem. 2008; 283: 1-19https://doi.org/10.1007/128_2007_3
        • Fu D.
        • Calvo J.A.
        • Samson L.D.
        Balancing repair and tolerance of DNA damage caused by alkylating agents.
        Nat Rev Cancer. 2012; 12: 104-120https://doi.org/10.1038/nrc3185
        • Radis C.D.
        • Kahl L.E.
        • Baker G.L.
        • Wasko M.C.
        • Cash J.M.
        • Gallatin A.
        • et al.
        Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.
        Arthritis Rheum. 1995; 38: 1120-1127https://doi.org/10.1002/art.1780380815
        • Johnson A.A.
        • Akman K.
        • Calimport S.R.
        • Wuttke D.
        • Stolzing A.
        • de Magalhaes J.P.
        The role of DNA methylation in aging, rejuvenation, and age-related disease.
        Rejuvenation Res. 2012; 15: 483-494https://doi.org/10.1089/rej.2012.1324
        • Hofstatter E.W.
        • Horvath S.
        • Dalela D.
        • Gupta P.
        • Chagpar A.B.
        • Wali V.B.
        • et al.
        Increased epigenetic age in normal breast tissue from luminal breast cancer patients.
        Clin Epigenetics. 2018; 10: 112https://doi.org/10.1186/s13148-018-0534-8
        • Horvath S.
        DNA methylation age of human tissues and cell types.
        Genome Biol. 2013; 14: R115https://doi.org/10.1186/gb-2013-14-10-r115
        • Yao S.
        • Hu Q.
        • Kerns S.
        • Yan L.
        • Onitilo A.A.
        • Misleh J.
        • et al.
        Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.
        Clin Epigenetics. 2019; 11: 45https://doi.org/10.1186/s13148-019-0641-1
        • Yang G.S.
        • Mi X.
        • Jackson-Cook C.K.
        • Starkweather A.R.
        • Lynch Kelly D.
        • Archer K.J.
        • et al.
        Differential DNA methylation following chemotherapy for breast cancer is associated with lack of memory improvement at one year.
        Epigenetics. 2020; 15: 499-510https://doi.org/10.1080/15592294.2019.1699695
        • Oh J.
        • Lee Y.D.
        • Wagers A.J.
        Stem cell aging: mechanisms, regulators and therapeutic opportunities.
        Nat Med. 2014; 20: 870-880https://doi.org/10.1038/nm.3651
        • Pervaiz S.
        • Taneja R.
        • Ghaffari S.
        Oxidative stress regulation of stem and progenitor cells.
        Antioxid Redox Signal. 2009; 11: 2777-2789https://doi.org/10.1089/ars.2009.2804
        • Kemp K.
        • Morse R.
        • Wexler S.
        • Cox C.
        • Mallam E.
        • Hows J.
        • et al.
        Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.
        Ann Hematol. 2010; 89: 701-713https://doi.org/10.1007/s00277-009-0896-2
        • Gardner R.V.
        • Lerner C.
        • Astle C.M.
        • Harrison D.E.
        Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay.
        Cancer Chemother Pharmacol. 1993; 32: 450-454https://doi.org/10.1007/bf00685889
        • Campisi J.
        Aging, cellular senescence, and cancer.
        Annu Rev Physiol. 2013; 75: 685-705https://doi.org/10.1146/annurev-physiol-030212-183653
        • Wong K.K.
        • Maser R.S.
        • Bachoo R.M.
        • Menon J.
        • Carrasco D.R.
        • Gu Y.
        • et al.
        Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing.
        Nature. 2003; 421: 643-648https://doi.org/10.1038/nature01385
        • Willeit P.
        • Willeit J.
        • Mayr A.
        • Weger S.
        • Oberhollenzer F.
        • Brandstatter A.
        • et al.
        Telomere length and risk of incident cancer and cancer mortality.
        JAMA. 2010; 304: 69-75https://doi.org/10.1001/jama.2010.897
        • Diker-Cohen T.
        • Uziel O.
        • Szyper-Kravitz M.
        • Shapira H.
        • Natur A.
        • Lahav M.
        The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
        Leuk Lymphoma. 2013; 54: 2023-2029https://doi.org/10.3109/10428194.2012.757765
        • Unryn B.M.
        • Hao D.
        • Gluck S.
        • Riabowol K.T.
        Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer.
        Clin Cancer Res. 2006; 12: 6345-6350https://doi.org/10.1158/1078-0432.CCR-06-0486
        • Sebastiani P.
        • Thyagarajan B.
        • Sun F.
        • Schupf N.
        • Newman A.B.
        • Montano M.
        • et al.
        Biomarker signatures of aging.
        Aging Cell. 2017; 16: 329-338https://doi.org/10.1111/acel.12557
        • Puzianowska-Kuznicka M.
        • Owczarz M.
        • Wieczorowska-Tobis K.
        • Nadrowski P.
        • Chudek J.
        • Slusarczyk P.
        • et al.
        Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study.
        Immun Ageing. 2016; 13: 21https://doi.org/10.1186/s12979-016-0076-x
        • Logan R.M.
        • Stringer A.M.
        • Bowen J.M.
        • Gibson R.J.
        • Sonis S.T.
        • Keefe D.M.
        Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.
        Cancer Biol Ther. 2008; 7: 1139-1145https://doi.org/10.4161/cbt.7.7.6207
        • Pusztai L.
        • Mendoza T.R.
        • Reuben J.M.
        • Martinez M.M.
        • Willey J.S.
        • Lara J.
        • et al.
        Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
        Cytokine. 2004; 25: 94-102https://doi.org/10.1016/j.cyto.2003.10.004
        • White C.M.
        • Martin B.K.
        • Lee L.F.
        • Haskill J.S.
        • Ting J.P.
        Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells.
        Cancer Immunol Immunother. 1998; 46: 104-112https://doi.org/10.1007/s002620050468
        • Raghu Nadhanan R.
        • Abimosleh S.M.
        • Su Y.W.
        • Scherer M.A.
        • Howarth G.S.
        • Xian C.J.
        Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss.
        Am J Physiol Endocrinol Metab. 2012; 302: E1440-E1449https://doi.org/10.1152/ajpendo.00587.2011
        • Cheung Y.T.
        • Krull K.R.
        Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: a systematic review.
        Neurosci Biobehav Rev. 2015; 53: 108-120https://doi.org/10.1016/j.neubiorev.2015.03.016
        • Krull K.R.
        • Bhojwani D.
        • Conklin H.M.
        • Pei D.
        • Cheng C.
        • Reddick W.E.
        • et al.
        Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.
        J Clin Oncol. 2013; 31: 2182-2188https://doi.org/10.1200/JCO.2012.46.7944
        • Oeffinger K.C.
        • Mertens A.C.
        • Sklar C.A.
        • Kawashima T.
        • Hudson M.M.
        • Meadows A.T.
        • et al.
        Chronic health conditions in adult survivors of childhood cancer.
        N Engl J Med. 2006; 355: 1572-1582https://doi.org/10.1056/NEJMsa060185
        • Hoffman M.C.
        • Mulrooney D.A.
        • Steinberger J.
        • Lee J.
        • Baker K.S.
        • Ness K.K.
        Deficits in physical function among young childhood cancer survivors.
        J Clin Oncol. 2013; 31: 2799-2805https://doi.org/10.1200/JCO.2012.47.8081
        • Ness K.K.
        • Morris E.B.
        • Nolan V.G.
        • Howell C.R.
        • Gilchrist L.S.
        • Stovall M.
        • et al.
        Physical performance limitations among adult survivors of childhood brain tumors.
        Cancer. 2010; 116: 3034-3044https://doi.org/10.1002/cncr.25051
        • Reeve B.B.
        • Potosky A.L.
        • Smith A.W.
        • Han P.K.
        • Hays R.D.
        • Davis W.W.
        • et al.
        Impact of cancer on health-related quality of life of older Americans.
        J Natl Cancer Inst. 2009; 101: 860-868https://doi.org/10.1093/jnci/djp123
        • Ferrell B.R.
        • Hassey Dow K.
        Quality of life among long-term cancer survivors.
        Oncology (Williston Park). 1997; 11 (71; discussion 72, 75–6): 565-568
        • Meropol N.J.
        • Egleston B.L.
        • Buzaglo J.S.
        • Benson 3rd, A.B.
        • Cegala D.J.
        • Diefenbach M.A.
        • et al.
        Cancer patient preferences for quality and length of life.
        Cancer. 2008; 113: 3459-3466https://doi.org/10.1002/cncr.23968
        • Braun D.P.
        • Gupta D.
        • Staren E.D.
        Quality of life assessment as a predictor of survival in non-small cell lung cancer.
        BMC Cancer. 2011; 11: 353https://doi.org/10.1186/1471-2407-11-353
        • Braun D.P.
        • Gupta D.
        • Staren E.D.
        Predicting survival in prostate cancer: the role of quality of life assessment.
        Support Care Cancer. 2012; 20: 1267-1274https://doi.org/10.1007/s00520-011-1213-x
        • Guy Jr., G.P.
        • Yabroff K.R.
        • Ekwueme D.U.
        • Rim S.H.
        • Li R.
        • Richardson L.C.
        Economic burden of chronic conditions among survivors of cancer in the United States.
        J Clin Oncol. 2017; 35: 2053-2061https://doi.org/10.1200/JCO.2016.71.9716